A JAK Inhibitor for Treatment of Rheumatoid Arthritis: The Baricitinib Experience.

Taylor, Peter C; Laedermann, Cedric; Alten, Rieke; Feist, Eugen; Choy, Ernest; Haladyj, Ewa; De La Torre, Inmaculada; Richette, Pascal; Finckh, Axel; Tanaka, Yoshiya

Taylor, Peter C; Laedermann, Cedric; Alten, Rieke; Feist, Eugen; Choy, Ernest; Haladyj, Ewa; De La Torre, Inmaculada; Richette, Pascal; Finckh, Axel; Tanaka, Yoshiya.

Afiliación

Taylor PC; Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford, Oxford OX3 7LD, UK.
Laedermann C; Eli Lilly and Company, Indianapolis, IN 46285, USA.
Alten R; Internal Medicine II, Rheumatology, SCHLOSSPARK-KLINIK, University Medicine Berlin, 14059 Berlin, Germany.
Feist E; Department of Rheumatology, Helios Clinic Vogelsang-Gommern, Cooperation Partner of the Otto-von-Guericke University Magdeburg, 39245 Magdeburg, Germany.
Choy E; Division of Infection and Immunity, Cardiff University School of Medicine, Cardiff CF14 4YS, UK.
Haladyj E; Eli Lilly and Company, Indianapolis, IN 46285, USA.
De La Torre I; Eli Lilly and Company, Indianapolis, IN 46285, USA.
Richette P; Service de Rhumatologie, Hôpital Lariboisière, 75010 Paris, France.
Finckh A; Inserm, UMR-S 1132, Bioscar, Université de Paris, 75010 Paris, France.
Tanaka Y; Division of Rheumatology, Department of Medicine, Geneva University Hospitals, 1205 Geneva, Switzerland.

J Clin Med ; 12(13)2023 Jul 06.

Article en En | MEDLINE | ID: mdl-37445562

Palabras clave

baricitinib; randomised controlled trial; real-world evidence; rheumatoid arthritis

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Guideline / Observational_studies / Risk_factors_studies Idioma: En Revista: J Clin Med Año: 2023 Tipo del documento: Article País de afiliación: Reino Unido

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google